---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062263"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:07:41.483951+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17

## Summary
- Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.
- Nasdaq ticker symbol changes from FWBI to ENTO at market open on May 17.
- Rebranding follows recent business combination with ImmunogenX, reflecting GI-focused pipeline.
- Lead asset latiglutenase for celiac disease; Phase 3 trial expected to begin early 2025.

## SEC filing metadata
- accession: 0001104659-24-062263
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/0001104659-24-062263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/tm2414628d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062263
- JSON: https://secwatch.observer/filing/0001104659-24-062263.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062263.txt

## Key facts
- Governance Changes
  GridAI Technologies Corp.: Company changed its corporate name from First Wave BioPharma, Inc. to Entero Therapeutics, Inc. via amendment to Amended and Restated Certificate of Incorporation (effective 2024-05-17).
  - Change: charter amendment
  - Effective: 2024-05-17
  source text: On May 15, 2024, First Wave BioPharma, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from "First Wave BioPharma, Inc." to "Entero Therapeutics, Inc." (the "Name Change Amendment"). Pursuant ot the Name Change Amendment, this name change is effective as of May 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/0001104659-24-062263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.